OncoCyte Corporation (OCX)
NASDAQ: OCX
· Real-Time Price · USD
3.38
-0.06 (-1.74%)
At close: May 23, 2025, 3:59 PM
3.37
-0.30%
After-hours: May 23, 2025, 04:04 PM EDT
OncoCyte Revenue Breakdown
| Period Ending | Dec 31, 2024 |
|---|---|
| Pharma Services Revenue | 1.86M |
| Pharma Services Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.32M | 3.4M | 3.61M | 3.26M | 3.52M | 2.33M | 3.2M | 3.85M | 4.11M | -4M | 9.21M | 9.03M | 8.89M | 7.45M | 8.43M | 10.61M | 7.02M | 5.28M | 6.56M | 5.32M | 6.12M | 5.21M | 3.63M | 3.95M | 2.65M | 2.84M | 1.5M | 1.9M | 2.44M | 2.38M | 5M | 1.59M | 2.7M | 1.66M | 1.22M | 1.34M | 1.24M | 2.11M | 1.31M | 519K | 250K |
| Selling, General, and Administrative Revenue Growth | +27.16% | -5.82% | +10.67% | -7.36% | +50.77% | -27.06% | -16.99% | -6.14% | -202.78% | -143.39% | +1.96% | +1.61% | +19.30% | -11.56% | -20.56% | +51.14% | +32.82% | -19.49% | +23.34% | -12.98% | +17.48% | +43.31% | -8.14% | +48.98% | -6.65% | +90.04% | -21.43% | -22.13% | +2.52% | -52.29% | +214.01% | -40.99% | +62.24% | +36.42% | -8.83% | +7.56% | -41.09% | +60.82% | +152.79% | +107.60% | n/a |
| Research and Development Revenue | 2.92M | 1.92M | 2.82M | 2.45M | 1.93M | 2.55M | 2.19M | 2.44M | 2.13M | -7.82M | 4.42M | 5.57M | 5.13M | 4.59M | 3.14M | 2.54M | 3.36M | 1.8M | 2.62M | 3.23M | 2.16M | 2.32M | 1.63M | 1.51M | 1.34M | 1.2M | 1.53M | 2.32M | 1.46M | 1.51M | 1.84M | 2M | 1.83M | 1.43M | 1.36M | 1.2M | 1.69M | 1.43M | 1.09M | 886K | 1.12M |
| Research and Development Revenue Growth | +52.29% | -31.84% | +14.84% | +26.97% | -24.15% | +16.57% | -10.27% | +14.48% | -127.19% | -276.93% | -20.69% | +8.70% | +11.70% | +46.12% | +23.85% | -24.52% | +86.72% | -31.17% | -18.91% | +49.37% | -6.86% | +42.65% | +7.76% | +12.29% | +11.54% | -21.15% | -34.24% | +58.93% | -3.05% | -17.92% | -8.06% | +8.89% | +28.16% | +4.99% | +14.06% | -29.25% | +18.19% | +30.62% | +23.48% | -20.68% | n/a |
| Sales and Marketing Revenue | 1.21M | 1.2M | 1.04M | 853K | 84K | 107K | 713K | 81K | 695K | -589K | 407K | 3.52M | 3.24M | 3.31M | 2.93M | 2.67M | 2.25M | 1.87M | 1.57M | 1.56M | 1.49M | 1.01M | 630K | 318K | 205K | 270K | 184K | 569K | 658K | 600K | 710K | 477K | 655K | 543K | 156K | 270K | 228K | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +0.33% | +15.24% | +22.27% | +915.48% | -21.50% | -84.99% | +780.25% | -88.35% | -218.00% | -244.72% | -88.44% | +8.80% | -2.18% | +12.90% | +9.65% | +18.59% | +20.28% | +19.52% | +0.38% | +4.83% | +47.38% | +60.48% | +98.11% | +55.12% | -24.07% | +46.74% | -67.66% | -13.53% | +9.67% | -15.49% | +48.85% | -27.18% | +20.63% | +248.08% | -42.22% | +18.42% | n/a | n/a | n/a | n/a | n/a |